Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hemophilia A
Open-data reference.
42 US clinical trials · 15 currently recruiting
Active & Recent Trials
Hemophilia A Research Program
University of Washington
NCT07414511
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Pfizer
NCT05145127
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
Pfizer
NCT05568719
Treatment of Hemophilia A Patients With FVIII Inhibitors
Emory University
NCT04023019
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
Pfizer
NCT05611801
Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis
Wayne State University
NCT05022459
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
Hoffmann-La Roche
NCT05987449
Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A
Washington Institute for Coagulation
NCT04131036
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
Equilibra Bioscience
NCT06349473
Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
Octapharma
NCT05936580
POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies
University of Texas Southwestern Medical Center
NCT04690322
A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
Sanofi
NCT06145373
ASC618 Gene Therapy in Hemophilia A Patients
ASC Therapeutics
NCT04676048
A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
Hoffmann-La Roche
NCT07226206
SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
Emory University
NCT04563520
Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A
Bayer
NCT03932201
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A
Bioverativ, a Sanofi company
NCT04644575
A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A
Baxalta now part of Shire
NCT04158934
A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A
Sanofi
NCT05911763
Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults
Pfizer
NCT04370054
Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A
Spark Therapeutics
NCT03432520
Gene Therapy for Haemophilia A.
University College, London
NCT03001830
Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"
Bayer
NCT03588299
Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A
Medical College of Wisconsin
NCT03818763
Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study
Weill Medical College of Cornell University
NCT00936312
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
CSL Behring
NCT01486927
A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors
Genzyme, a Sanofi Company
NCT03417245
ADVATE Post Authorization Safety Surveillance
Baxalta now part of Shire
NCT00214734
A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors
Hoffmann-La Roche
NCT02795767
Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery
Baxalta now part of Shire
NCT00357656
Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment
Bayer
NCT00623480
A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A
Bayer
NCT01233258
Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A
Bioverativ, a Sanofi company
NCT04759131
Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery
Wyeth is now a wholly owned subsidiary of Pfizer
NCT00243659
Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980
Bayer
NCT00629837
Prophylaxis Regimen for Hemophilia A Patients
Bayer
NCT05036278
Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia
Virginia Commonwealth University
NCT01090206
Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies
Swedish Orphan Biovitrum
NCT03103542
Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration
Bayer
NCT01184820
Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Damoctocog Alfa Pegol (LIFE ACTIVE Study)
Bayer
NCT04091386
A Study of BAX 888 in Male Adults With Severe Hemophilia A
Baxalta now part of Shire
NCT03370172
Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers
Emory University
NCT02506023
Phase Distribution
| Phase | Trial count |
|---|---|
| Early Phase 1 | 11 |
| Phase 2 | 1 |
| Phase 3 | 12 |
| Phase 4 | 6 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Hemophilia A Trial Landscape
ClinicalTrials.gov lists 42 US studies indexed under Hemophilia A, and 15 of those are currently open to recruitment — roughly 36% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Hemophilia A shows 18 late-stage studies (Phase 3 and Phase 4 combined) alongside 12 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Hemophilia A is led by Bayer with 8 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 42 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Hemophilia A?
PlainTrial tracks 42 US clinical trials for Hemophilia A, of which 15 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Hemophilia A?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.